CervoMed Inc. reports clinical-stage biotechnology developments centered on neflamapimod, an oral small-molecule drug candidate for age-related brain disorders. Company news most often covers dementia with Lewy bodies, the Phase 2b RewinD-LB trial, biomarker and MRI analyses, pharmacokinetic work, formulation and dosing disclosures, and regulatory interactions tied to later-stage development.
Updates also include financial results, grant revenue trends, investor conference presentations, shareholder voting matters, governance items, and capital-structure disclosures. CervoMed has also reported neflamapimod's inclusion in the UK EXPERTS-ALS platform for amyotrophic lateral sclerosis research.
CervoMed (NASDAQ: CRVO), a clinical-stage company developing treatments for age-related neurologic disorders, announced its expected inclusion in the Russell 2000® and Russell 3000® Indexes, effective July 1, 2024.
This inclusion follows the 2024 Russell U.S. Indexes annual reconstitution, which captures the 4,000 largest U.S. stocks by market capitalization as of April 30, 2024.
CEO John Alam emphasized the importance of this milestone, citing it as a recognition of CervoMed's progress in advancing neflamapimod, a potential treatment for dementia with Lewy bodies (DLB).
The inclusion is expected to heighten awareness of CervoMed as it approaches the reporting of topline results from the Phase 2b RewinD-LB trial in December 2024.
CervoMed has completed enrollment for its Phase 2b RewinD-LB clinical trial, testing neflamapimod in patients with dementia with Lewy bodies (DLB). Topline data is expected in December 2024. This trial aims to address unmet needs in DLB treatment, targeting patients without Alzheimer’s disease (AD) co-pathology. CEO John Alam highlighted the significance of enrolling a pure DLB patient population. Kelly Blackburn, SVP of Clinical Development, noted the rapid enrollment due to high patient interest. Eligibility criteria included a DLB diagnosis, specific Clinical Dementia Rating scores, and low plasma ptau181 levels.
CervoMed (NASDAQ: CRVO) has announced the appointment of William (Bill) Elder as Chief Financial Officer, effective June 1, 2024. Mr. Elder, who will also continue his role as General Counsel and Corporate Secretary, will succeed William Tanner. Tanner will remain with the company as a consultant. CEO John Alam expressed confidence in Elder's expertise in biopharmaceutical and financial operations during this critical phase. The company's RewinD-LB Phase 2b clinical trial is set to complete enrollment in Q2 2024, with efficacy results expected in Q4 2024. Elder's financial background includes roles at Diffusion Pharmaceuticals and Dechert LLP. He holds degrees from the University of Pennsylvania, Villanova University, and Tufts University.
CervoMed, a clinical-stage company developing treatments for age-related neurological disorders, reported its Q1 2024 financial results. The company is on track to complete enrollment for its RewinD-LB Phase 2b trial evaluating neflamapimod in DLB patients by 2Q 2024, with topline data expected in 4Q 2024.
CervoMed completed a private placement of up to $149.4 million in early 2Q 2024, with $50 million received upfront. Cash and cash equivalents as of March 31, 2024, were $6.4 million, excluding the private placement proceeds.
Grant revenue increased to $2.3 million for Q1 2024, while R&D expenses rose to $2.8 million due to the RewinD-LB trial. G&A expenses increased to $2.1 million due to higher operational costs following a reverse merger in August 2023. The company reported an operating loss of $2.6 million but net income of $2.5 million for Q1 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.